Apparatus

H-Drugs in the leading international journal again!

In a rural area of Britain, a team of 100 scientists and engineers first used low-cost technologies to develop mobile phones and the aviation industry. Later, these technologies were used to research robot arms, which can be specially used for minimally invasive surgery.

Scientists from MIT designed a microfluidic device to capture and count circulating plasma cells in small samples of blood. This technique can only be carried out through routine blood drawing, which is expected to reduce the pain of patients' myeloma testing.

Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!

Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

A new generation of oral selective estrogen receptor degrader, elastostat, has shown promise in clinical studies over standard second-line treatments such as fulvestrant for the treatment of patients with metastatic hormone receptor-positive breast cancer.

SKB264 is currently in Phase II and Phase III clinical trials as a single agent/combination for multiple tumour types.

Accelerating and simplifying the development and manufacturing process of cell and gene therapies.

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.